Patient advocacy influential in drug development, says panel

Share this article:

Patient advocacy groups are an increasingly valuable resource for pharma manufacturers and FDA throughout the drug development process, since they provide, among other things, a crucial perspective, according to a New York Pharma Forum (NYPF) panel last week.

Panelist James Valentine, a program analyst at FDA's Office of Special Health Issues, said patient advocates serve not only as speakers at FDA's public meetings and workshops, but that they “ultimately add legitimacy and value to the process of medical product development,” according to slides provided to MM&M by the NYPF.

Genentech's associate director of advocacy relations, Kristin Reed, also a panelist in the discussion, said in a statement that Genentech has learned to communicate with patient advocacy groups, even if company objectives don't always align with patient insights. “Sharing information and hearing their viewpoints on important decisions builds long-term relationships,” Reed said in the statement. “We never underestimate these groups – they are extremely well-informed and sophisticated.” Reed did not immediately respond to a request for comment, and slides from her presentation were not available.

Terri Cooper, principle and leader, national R&D life sciences practice at Deloitte Consulting, said patient advocacy groups can help resolve patients' medical bills, support orphan diseases and raise money and awareness to jumpstart research, create networks to expedite clinical trial participation and reduce costs, as well as lobby for formulary access, according to the slides.

The panel, titled "The Influence of Patient Groups on Drug Development," was convened as part of the NYPF's 21st annual general assembly, on December 3 in New York. The NYPF is a nonprofit intended to encourage dialogue among US, Japanese, and other international biopharma execs on global issues of common interest, according to a statement.

Many pharmaceutical companies partnered with patient advocacy groups for educational campaigns in 2010, and an Epsilon survey showed that third parties – like non-profits and government – lend credibility to health information online, especially where pharma is involved.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...